Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
1. Number of Data-submitting Facilities* (2,289 facilities)

11.5% (6 facilities)
≧
900
beds
900
床以上
N=52

88.5% (46 facilities)

17.4% (59 facilities)
500- 899 beds
500～899
床
N=339

82.6% (280 facilities)

JANIS
Members†200- 499 beds
200～499
床51.2% (1,060 facilities)

N=2,072

JANIS NonMembers‡

48.8% (1,012 facilities)

15.7% (903 facilities)
<
200
beds
200
床未満

84.3% (4,839 facilities)

N=5,742

0

10

20

30

40

50

60

70

80

90

100 (%)* Data-submitting Facilities indicate facilities included in Annual Open Report 2022.
† Number of JANIS Members = Number of facilities included in Annual Open Report 2022.
‡ Number of JANIS Non-members = (Number of facilities nationwide in 2021¶) - (Number of facilities included in Annual Open Report 2022)

Number of beds

Number of facilities nationwide in
2021¶

Number of Facilities Included in Annual Open Report 2022
(percentage of facilities nationwide)≧ 900 beds52

46 ( 88.5% )500 - 899 beds

339

280 ( 82.6% )200 - 499 beds

2,072

1,060 ( 51.2% )< 200 beds

5,742

903 ( 15.7% )Unknown
Total

-

0 (

8,205

-

)

2,289 ( 27.9% )¶ Data of medical facilities is referred to Vital Statistics 2021.

1
This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
2. Number of Data-submitting Facilities,
Specimens and Isolates Counted by Specimen Source
Specimen

Number ofSourcefacilities

Number of specimens
Before deduplication

After deduplication

Number of culturepositive specimens

Before deduplication

After deduplication

Number of isolates
Before deduplication

After deduplication

Respiratory

2,285 2,011,897 1,276,063 1,178,379

814,450 2,456,337 1,935,869

Urine

2,282 1,257,562

974,955

734,356

606,958 1,138,570 1,003,943

Feces

2,253

372,968

193,056

146,485

353,291

283,124

Blood

2,271 3,017,336 1,170,168

402,445

220,672

453,350

265,879

Cerebrospina
l fluid

1,519

76,29655,851

3,454

2,524

3,782

2,826

Others2,281 1,398,972

829,703602,182408,617 1,085,282

842,160

Total

2,289 8,279,158 4,679,708 3,113,872 2,199,706 5,490,612 4,333,801

517,095

Inpatient specimens are counted.
De-duplication removed repeated isolates of the same species isolated from a patient within 30 days
regardless of specimen type (see Appendix I).
All isolated bacteria except Isolated Bacterial Code 9999 (comments only) are counted.
Each specimen includes corresponding specimen source codes as below.
Respiratory : 101 (Sputum), 102 (Endotracheal aspirate), 103 (Bronchoalveolar lavage), 104 (Throat),
105 (Nasal), 106 (Oral), 107 (Lung biopsy), 109 (Other Respiratory) and 404 (Pleural
effusion)
Urinary : 201 (Urine), 202 (Urine collected by catheter), 203 (Urine obtained from indwelling catheter)and 206 (Catheterized urine)
Feces : 301 (Feces)
Blood : 401 (Venous blood) and 402 (Arterial blood)
Cerebrospinal fluid : 403 (Cerebrospinal fluid)
Others : Specimen codes not indicated above
Specimen Source Code : https://janis.mhlw.go.jp/section/kensa.html
2This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
3. Isolated Bacteria from Blood Specimens
Blood Isolates
76,830 (16.9%)
44,042 (16.6%)
66,239 (14.6%)
31,095 (11.7%)
48,629 (10.7%)30,901 (11.6%)
41,865 (9.2%)
28,784 (10.8%)
29,942 (6.6%)
17,030 (6.4%)
13,910 (3.1%)
8,315 (3.1%)
13,740 (3.0%)
7,716 (2.9%)
10,128 (2.2%)
6,171 (2.3%)
9,470 (2.1%)
5,079 (1.9%)
Before de-duplication
8,410 (1.9%)
3,873 (1.5%)
After de-duplication
7,107 (1.6%)
4,659 (1.8%)
7,027 (1.6%)
4,025 (1.5%)
Others(Before de-duplication)
5,874 (1.3%)
103,204 (22.8%)
4,255 (1.6%)
5,584 (1.2%)
Others(After de-duplication)
3,291 (1.2%)
63,312 (23.8%)
5,391 (1.2%)
3,331 (1.3%)

Escherichia coli
Staphylococcus aureus
Staphylococcus epidermidis
Coagulase-negative staphylococci (CNS)*
Klebsiella pneumoniae
Enterococcus faecalis
Pseudomonas aeruginosaEnterococcus faecium
Enterobacter cloacae complex†
Candida albicans
Corynebacterium spp.
Klebsiella oxytoca
Staphylococcus spp.
Bacillus cereus
Streptococcus spp.
0

20,00040,00060,00080,000100,000*Coagulase-negative staphylococci correspond to Isolated Bacterial Codes 1311, 1313-1325 (except Code 1312,Staphylococcus epidermidis)†E. cloacae complex correspond to Isolated Bacterial Codes 2151，2155，2157-2161

All inpatient speciments are counted (contaminants are not excluded).
De-duplication removed repeated isolates of the same species isolated from a patient within 30 days
regardless of specimen type (see Appendix I).
Others include Isolated Bacterial Code 9998 (other species) and bacteria ranked 16th and lower.
All isolated bacteria except Bacterial Code 9999 (comments only) are counted.
Specimen reported as Specimen Source Code 401 (venous blood) and Code 402 (arterial blood) arecounted.
Percentage of Corresponding Blood Isolates =(Number of Corresponding Blood Isolates ) / (Total Number of Blood Isolates ) x 100
Isolated Bacterial Code : https://janis.mhlw.go.jp/section/kensa.html
Specimen Source Code : https://janis.mhlw.go.jp/section/kensa.html
3This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
3. Isolated Bacteria from Cerebrospinal Fluid Specimens
Cerebrospinal Fluid Isolates
597 (15.8%)
406 (14.4%)
511 (13.5%)
360 (12.7%)454 (12.0%)350 (12.4%)
212 (5.6%)
168 (5.9%)
176 (4.7%)
157 (5.6%)
133 (3.5%)
98 (3.5%)
127 (3.4%)
88 (3.1%)
108 (2.9%)
86 (3.0%)102 (2.7%)
64 (2.3%)
Before de-duplication
95 (2.5%)
57 (2.0%)
After de-duplication
92 (2.4%)
53 (1.9%)89 (2.4%)
56 (2.0%)
Others(Before de-duplication)
88 (2.3%)855 (22.6%)
65 (2.3%)
73 (1.9%)
Others(After de-duplication)
71 (2.5%)
679 (24.0%)
70 (1.9%)68 (2.4%)

Staphylococcus epidermidis
Staphylococcus aureus
Coagulase-negative staphylococci (CNS)*
Corynebacterium spp.
Propionibacterium acnes
Cryptococcus neoformans
Klebsiella pneumoniae
Escherichia coli
Enterococcus faecalisEnterobacter cloacae complex†
Staphylococcus spp.
Klebsiella aerogenes
Pseudomonas aeruginosa
Streptococcus agalactiae
Streptococcus pneumoniae
0

200

400

600

800

*Coagulase-negative staphylococci correspond to Isolated Bacterial Codes 1311, 1313-1325 (except Code 1312,Staphylococcus epidermidis)†E. cloacae complex correspond to Isolated Bacterial Codes 2151，2155，2157-2161

All inpatient speciments are counted (contaminants are not excluded).
De-duplication removed repeated isolates of the same species isolated from a patient within 30 days
regardless of specimen type (see Appendix I).
Others include Isolated Bacterial Code 9998 (other species) and bacteria ranked 16th and lower.
All isolated bacteria except Bacterial Code 9999 (comments only) are counted.
Specimen reported as Specimen Source Code 403 (Cerebrospinal Fluid Samples) are counted.
Percentage of Corresponding Cerebrospinal Fluid Isolates =(Number of Corresponding Cerebrospinal Fluid Isolates ) / (Total Number of Cerebrospinal Fluid Isolates )x 100
Isolated Bacterial Code : https://janis.mhlw.go.jp/section/kensa.html
Specimen Source Code : https://janis.mhlw.go.jp/section/kensa.html
4This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
3. Isolated Bacteria from Respiratory Specimens
Respiratory Isolates
351,099 (14.3%)
257,538 (13.3%)
262,461 (10.7%)
217,386 (11.2%)
164,648 (6.7%)
112,502 (5.8%)
147,855 (6.0%)
116,912 (6.0%)
140,740 (5.7%)
109,983 (5.7%)
120,393 (4.9%)
106,501 (5.5%)
116,869 (4.8%)
81,595 (4.2%)
107,853 (4.4%)
86,031 (4.4%)
74,602 (3.0%)
58,925 (3.0%)
Before de-duplication
58,516 (2.4%)
48,803 (2.5%)
After de-duplication
45,513 (1.9%)
31,653 (1.6%)
44,072 (1.8%)
36,497 (1.9%)
Others(Before de-duplication)
43,218 (1.8%)
698,985 (28.5%)
38,941 (2.0%)
40,492 (1.6%)
Others(After de-duplication)
32,290 (1.7%)
566,623 (29.3%)
39,021 (1.6%)
33,689 (1.7%)

Staphylococcus aureus
α-Streptococcus
Pseudomonas aeruginosa
Candida albicans
Corynebacterium spp.
Neisseria spp.
Coagulase-negative staphylococci (CNS)*
Klebsiella pneumoniae
Escherichia coli
Candida spp.
Stenotrophomonas maltophilia
Candida glabrataγ-Streptococcus
Enterobacter cloacae complex†
Streptococcus agalactiae
0

100,000

200,000

300,000

400,000*Coagulase-negative staphylococci correspond to Isolated Bacterial Codes 1311, 1313-1325 (except Code 1312,Staphylococcus epidermidis)†E. cloacae complex correspond to Isolated Bacterial Codes 2151，2155，2157-2161

All inpatient speciments are counted (contaminants are not excluded).
De-duplication removed repeated isolates of the same species isolated from a patient within 30 days
regardless of specimen type (see Appendix I).
Others include Isolated Bacterial Code 9998 (other species) and bacteria ranked 16th and lower.
All isolated bacteria except Bacterial Code 9999 (comments only) are counted.
Specimen reported as Specimen Source Code 101 (Sputum) and Code 102 (Endotracheal aspirate) and
Code 103 (Bronchoalveolar lavage) and Code 104 (Throat) and Code 105 (Nasal) and Code 106 (Oral) and
Code 107 (Lung biopsy) and Code 109 (Other(Respiratory)) and Code 404 (Pleural effusion) are counted.
Percentage of Corresponding Respiratory Isolates =(Number of Corresponding Respiratory Isolates ) / (Total Number of Respiratory Isolates ) x 100
Isolated Bacterial Code : https://janis.mhlw.go.jp/section/kensa.html
Specimen Source Code : https://janis.mhlw.go.jp/section/kensa.html
5This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
3. Isolated Bacteria from Urine Specimens
Urine Isolates
Escherichia coli
102,475 (9.0%)
92,449 (9.2%)
77,841 (6.8%)
63,506 (6.3%)
73,377 (6.4%)
65,069 (6.5%)
51,263 (4.5%)
45,989 (4.6%)
41,978 (3.7%)
31,410 (3.1%)
40,932 (3.6%)
38,845 (3.9%)
37,054 (3.3%)
31,257 (3.1%)
36,020 (3.2%)
32,529 (3.2%)
30,025 (2.6%)
26,740 (2.7%)
22,307 (2.0%)
21,345 (2.1%)
20,719 (1.8%)
18,991 (1.9%)
19,837 (1.7%)
15,971 (1.6%)
19,282 (1.7%)
18,589 (1.9%)
18,736 (1.6%)
17,074 (1.7%)

Enterococcus faecalis
Pseudomonas aeruginosa
Klebsiella pneumoniae
Corynebacterium spp.
Candida albicans
Coagulase-negative staphylococci (CNS)*Enterococcus faecium
Staphylococcus aureus
Proteus mirabilis
Streptococcus agalactiae
Enterococcus spp.
Candida glabrata
α-Streptococcus
Klebsiella oxytoca
0100,000

200,000

279,189 (24.5%)
245,263 (24.4%)

Before de-duplication
After de-duplication

Others(Before de-duplication)
267,535 (23.5%)
Others(After de-duplication)
238,916 (23.8%)

300,000

400,000*Coagulase-negative staphylococci correspond to Isolated Bacterial Codes 1311, 1313-1325 (except Code 1312,Staphylococcus epidermidis)

All inpatient speciments are counted (contaminants are not excluded).
De-duplication removed repeated isolates of the same species isolated from a patient within 30 days
regardless of specimen type (see Appendix I).
Others include Isolated Bacterial Code 9998 (other species) and bacteria ranked 16th and lower.
All isolated bacteria except Bacterial Code 9999 (comments only) are counted.
Specimen reported as Specimen Source Code 201 (Urine) and Code 202 (Urine collected by catheter) and
Code 203 (Urine obtained from indwelling catheter) and Code 206 (Catheterized urine) are counted.
Percentage of Corresponding Urine Isolates =(Number of Corresponding Urine Isolates ) / (Total Number of Urine Isolates ) x 100
Isolated Bacterial Code : https://janis.mhlw.go.jp/section/kensa.html
Specimen Source Code : https://janis.mhlw.go.jp/section/kensa.html
6This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
4. Number of Patients* and Isolation Rate of Major Bacteria

Number of Patients(Total Isolation Rate‡)

2018
Number of Specimensubmitting Patients
S. aureus

2019

2020

2021

2022

2,891,652 cases 2,972,343 cases 2,757,567 cases 2,788,100 cases 2,875,113 cases(447.8)(446.8)(406.0)(406.6)(413.2)※
391,316 cases(13.53%)400,094 cases(13.46%)367,976 cases(13.34%)360,912 cases(12.94%)370,067 cases(12.87%)

101,276 cases(3.50%)

99,317 cases(3.34%)

96,504 cases(3.50%)

96,363 cases(3.46%)

96,974 cases(3.37%)

39,194 cases(1.36%)

36,858 cases(1.24%)

18,663 cases(0.68%)

19,261 cases(0.69%)

16,752 cases(0.58%)

145,286 cases(5.02%)

148,000 cases(4.98%)

149,740 cases(5.43%)

154,125 cases(5.53%)

158,288 cases(5.51%)

56,809 cases(1.96%)

61,386 cases(2.07%)

63,205 cases(2.29%)

66,019 cases(2.37%)

68,511 cases(2.38%)

399,752 cases(13.82%)

412,498 cases(13.88%)409,632 cases(14.85%)412,514 cases(14.80%)423,962 cases(14.75%)

182,983 cases(6.33%)

185,294 cases(6.23%)

181,581 cases(6.58%)

183,202 cases(6.57%)

195,606 cases(6.80%)

E. cloacae complex--

71,852 cases(2.61%)

70,811 cases(2.54%)

73,402 cases(2.55%)

K. aerogenes--

35,576 cases(1.29%)

36,788 cases(1.32%)

39,878 cases(1.39%)

746,255 cases(25.81%)

765,479 cases(25.75%)762,174 cases(27.64%)775,411 cases(27.81%)

806,467 cases(28.05%)

187,958 cases(6.50%)

194,895 cases(6.56%)

192,320 cases(6.97%)

194,614 cases(6.98%)

202,196 cases(7.03%)

30,903 cases(1.07%)

29,514 cases(0.99%)

25,980 cases(0.94%)

25,247 cases(0.91%)

24,706 cases(0.86%)

S. epidermidis
S. pneumoniae
E. faecalis
E. faecium
E. coli
K. pneumoniae

Enterobacteriaceae
P. aeruginosa
Acinetobacter spp.

Distribution of
Isolation Rates (%)¶
among Data-submitting Facilities†

Inpatient specimens are counted.
*The number of duplicates within 30 days is not recounted for Patients with Major Bacteria andSpecimen-submitting Patients (See Appendix).
‡Total Isolation Rate = (Total Number of Patients with Major Bacteria for Data-submitting Facilities)/ (Total Number of Specimen-submitting Patients for Data-submitting Facilities) x 100¶Isolation Rate = (Number of Patients with Major Bacteria for Each Facility) / (Number of Specimensubmitting Patients for Each Facility) x 100†Data-submitting Facilities indicate facilities included in Annual Open Report 2022

7
This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
5. Number of Patients* and Isolation Rate of Specific AMR Bacteria

Number of Patients(Total Isolation Rate‡)

2018
Number of Specimen-submitting
Patients
Methicillin-resistant Staphylococcus
aureus(MRSA)
Vancomycin-resistant
Staphylococcus aureus(VRSA)
Vancomycin-resistant Enterococci(VRE)
Penicillin-resistant Streptococcus
pneumoniae(PRSP)
Multidrug-resistant Pseudomonas
aeruginosa(MDRP)
Multidrug-resistant Acinetobacterspp.(MDRA)
Carbapenem-resistantEnterobacteriaceae(CRE)
Carbapenem-resistantPseudomonas aeruginosa
3rd Generation Cephalosporinresistant Klebsiella pneumoniae
3rd Generation Cephalosporinresistant Escherichia coli
Fluoroquinolone-resistantEscherichia coli

2019

2020

2021

2022

Distribution of
Isolation Rates (%)¶
among Data-submitting Facilities†

2,891,652 cases 2,972,343 cases 2,757,567 cases 2,788,100 cases 2,875,113 cases(447.8)(446.8)(406.0)(406.6)(413.2)※
185,709 cases(6.42%)

192,320 cases(6.47%)

176,848 cases(6.41%)

167,858 cases(6.02%)

168,718 cases(5.87%)

0 cases(0.00%)

0 cases(0.00%)

0 cases(0.00%)

0 cases(0.00%)

0 cases(0.00%)

697 cases(0.02%)

1,176 cases(0.04%)

1,020 cases(0.04%)

1,490 cases(0.05%)

1,919 cases(0.07%)

14,139 cases(0.49%)

13,189 cases(0.44%)

7,389 cases(0.27%)

7,827 cases(0.28%)

7,184 cases(0.25%)

1,082 cases(0.04%)

1,099 cases(0.04%)

877 cases(0.03%)

800 cases(0.03%)

729 cases(0.03%)

99 cases(0.00%)

98 cases(0.00%)

92 cases(0.00%)

97 cases(0.00%)

101 cases(0.00%)

9,304 cases(0.32%)

9,721 cases(0.33%)

8,644 cases(0.31%)

9,030 cases(0.32%)

9,316 cases(0.32%)

21,202 cases(0.73%)

21,704 cases(0.73%)

21,137 cases(0.77%)

21,120 cases(0.76%)

20,789 cases(0.72%)

14,858 cases(0.51%)

16,982 cases(0.57%)

19,659 cases(0.71%)

21,898 cases(0.79%)

25,071 cases(0.87%)

92,653 cases(3.20%)

100,144 cases(3.37%)

102,624 cases(3.72%)

100,397 cases(3.60%)

104,260 cases(3.63%)

133,170 cases(4.61%)

141,668 cases(4.77%)

143,939 cases(5.22%)

141,674 cases(5.08%)

146,051 cases(5.08%)

Inpatient specimens with MIC Value reported by either the broth microdilution method or Etest are counted.
*The number of duplicates within 30 days is not recounted for the Patients with Specific AMR Bacteria
and Specimen-submitting Patients (See Appendix).
‡Total Isolation Rate = (Total Number of Patients with Specific AMR Bacteria for Data-submitting Facilities)/ (Total Number of Specimen-submitting Patients for Data-submitting Facilities) x 100¶Isolation Rate = (Number of Patients with Specific AMR Bacteria for Each Facility) / (Number of Specimensubmitting Patients for Each Facility) x 100†Data-submitting Facilities indicate facilities included in Annual Open Report 2022

8This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
6. Percentage of Facilities Reporting Specific AMR Bacteria
Percentage of Facilities Reporting Specific AMR Bacteria in 2022 (N=2,289)
Facilities reporting at least one corresponding Specific AMR Bacteria
Facilities reporting no corresponding Specific AMR Bacteria
Methicillin-resistantStaphylococcus aureus(MRSA)

2,283 (99.7%)

Vancomycin-resistantStaphylococcus aureus(VRSA)

2,289 (100.0%)

Vancomycin-resistant Enterococci(VRE)

196 (8.6%)

Multidrug-resistantPseudomonas aeruginosa(MDRP)

Multidrug-resistantAcinetobacter spp.(MDRA)

2,093 (91.4%)
1,233 (53.9%)

Penicillin-resistantStreptococcus pneumoniae(PRSP)

1,056 (46.1%)

332 (14.5%)

1,957 (85.5%)25 (1.1%)

2,264 (98.9%)
1,171 (51.2%)

Carbapenem-resistant Enterobacteriaceae(CRE)

6 (0.3%)

1,118 (48.8%)

Carbapenem-resistantPseudomonas aeruginosa

1,881 (82.2%)

408 (17.8%)

3rd Generation Cephalosporin-resistantKlebsiella pneumoniae

1,870 (81.7%)

419 (18.3%)

3rd Generation Cephalosporin-resistantEscherichia coli

2,207 (96.4%)

82 (3.6%)

Fluoroquinolone-resistant Escherichia coli

2,215 (96.8%)

74 (3.2%)

0

20

40

60

80

100 (%)

Percentage of Facilities Reporting Specific AMR Bacteria for the Past Five Years
2018

2019

2020

2021

2022

1,947

2,075

2,167

2,220

2,289

Methicillin-resistant Staphylococcus aureus(MRSA)

99.8%

99.8%

99.8%

99.8%

99.7%

Vancomycin-resistant Staphylococcus aureus(VRSA)

0.0%

0.0%

0.0%

0.0%

0.0%

Vancomycin-resistant Enterococci(VRE)

7.5%

7.8%

9.6%

9.1%

8.6%

Penicillin-resistant Streptococcus pneumoniae(PRSP)

67.8%

65.5%

58.0%

53.4%

53.9%

Multidrug-resistant Pseudomonas aeruginosa(MDRP)

Number of facilities included in Annual Open Report

22.2%

22.8%

18.1%

16.4%

14.5%

Multidrug-resistant Acinetobacter spp.(MDRA)

1.7%

1.4%

1.0%

0.8%

1.1%

Carbapenem-resistant Enterobacteriaceae(CRE)

55.2%

52.3%

51.2%

50.3%

51.2%

Carbapenem-resistant Pseudomonas aeruginosa

85.3%

84.5%

83.2%

82.2%

82.2%

3rd Generation Cephalosporin-resistant Klebsiella pneumoniae

78.6%

78.0%

79.2%

79.4%

81.7%

3rd Generation Cephalosporin-resistant Escherichia coli

96.1%

95.8%

96.1%

96.0%

96.4%

Fluoroquinolone-resistant Escherichia coli

96.9%

97.0%

96.9%

96.7%

96.8%

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Percentage of Facilities Reporting Specific AMR Bacteria = (Number of Facilities Reporting at Least one
Corresponding Specific AMR Bacteria) / (Number of Data-submitting Facilities)

9This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus aureus (ALL)†
S

SorI

I

IorR

R

ND

PCG (N=288,253)

PCG(N=288,253)

78,529 0(27.2%) (0.0%)0(0.0%)

0(0.0%)

209,720 4(72.8%) (0.0%)

MPIPC (N=243,386)

MPIPC(N=243,386)

132,528 0(54.5%) (0.0%)0(0.0%)

0(0.0%)

110,757 101(45.5%) (0.0%)

CEZ (N=346,659)

CEZ(N=346,659)

269,814 0(77.8%) (0.0%)

20,344(5.9%)

103(0.0%)

56,066 332(16.2%) (0.1%)

CFX

36,646 0(56.4%) (0.0%)0(0.0%)

0(0.0%)

28,374 11(43.6%) (0.0%)

236,804 3(71.7%) (0.0%)

7,723(2.3%)

120(0.0%)

82,804 2,907(25.1%) (0.9%)

146,371 0(47.4%) (0.0%)

18,345(5.9%)

161(0.1%)

143,823 1(46.6%) (0.0%)(N=331,565)

276,543 0(83.4%) (0.0%)

2,950(0.9%)

65(0.0%)

51,947 60(15.7%) (0.0%)

LVFX (N=349,500)

LVFX(N=349,500)

167,758 0(48.0%) (0.0%)

2,419(0.7%)

84(0.0%)

179,238 1(51.3%) (0.0%)

MINO (N=365,963)

MINO(N=365,963)

330,029 0(90.2%) (0.0%)

6,797(1.9%)

28(0.0%)

29,108(8.0%)

1(0.0%)ST (N=278,730)

ST(N=278,730)

277,143 0(99.4%) (0.0%)0(0.0%)

0(0.0%)

1,168(0.4%)

419(0.2%)VCM (N=358,032)

VCM(N=358,032)

357,999 0(100%) (0.0%)29(0.0%)

0(0.0%)

0(0.0%)

4(0.0%)TEIC (N=318,317)

TEIC(N=318,317)

318,221 0(100%) (0.0%)

16(0.0%)

0(0.0%)

13(0.0%)

67(0.0%)LZD (N=277,713)

LZD(N=277,713)

277,655 0(100%) (0.0%)0(0.0%)

0(0.0%)

56(0.0%)

2(0.0%)CFX (N=65,031)(N=65,031)
GM

GM (N=330,361)(N=330,361)
EM

EM (N=308,701)(N=308,701)
CLDM

CLDM (N=331,565)

0

10

20

30

40

50

60

70

80

90

100 (%)S

DAP(N=128,962)

DAP (N=128,962)
0

10

20

30

40

50

60

70

80

90

NS

128,631 331(99.7%) (0.3%)

ND

0(0.0%)

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† S. aureus corresponds to Isolated Bacterial Codes 1301 and 1303-1306.
Antibiogram is not created if the total number of isolates is less than 30.

10This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus aureus (MSSA)†
S

SorI

I

IorR

R

ND

PCG (N=143,105)

PCG(N=143,105)

71,288 0(49.8%) (0.0%)0(0.0%)

0(0.0%)

71,817 0(50.2%) (0.0%)

CVA/AMPC (N=28,097)

CVA/AMPC(N=28,097)

27,875 0(99.2%) (0.0%)0(0.0%)

0(0.0%)

36(0.1%)

186(0.7%)CEZ (N=167,376)

CEZ(N=167,376)

167,248 0(99.9%) (0.0%)60(0.0%)

0(0.0%)

67(0.0%)

1(0.0%)IPM (N=141,411)

IPM(N=141,411)

141,361 1(100%) (0.0%)

12(0.0%)

0(0.0%)

37(0.0%)

0(0.0%)

GM (N=159,788)

GM(N=159,788)

121,317 2(75.9%) (0.0%)

3,748(2.3%)

27(0.0%)

33,097 1,597(20.7%) (1.0%)

EM(N=149,705)

114,224 0(76.3%) (0.0%)

4,771(3.2%)

24(0.0%)

30,686 0(20.5%) (0.0%)

CLDM (N=158,285)

CLDM(N=158,285)

153,219 0(96.8%) (0.0%)632(0.4%)

1(0.0%)

4,409(2.8%)

LVFX (N=165,426)

LVFX(N=165,426)

136,563 0(82.6%) (0.0%)

1,754(1.1%)

17(0.0%)

27,092 0(16.4%) (0.0%)

MINO(N=172,471)

171,078 0(99.2%) (0.0%)456(0.3%)

1(0.0%)

936(0.5%)

0(0.0%)

ST(N=132,868)

132,123 0(99.4%) (0.0%)0(0.0%)

0(0.0%)

421(0.3%)

324(0.2%)EM (N=149,705)

MINO (N=172,471)

ST (N=132,868)

0

10

20

30

40

50

60

70

80

24
(0.0%)

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† S. aureus (MSSA) corresponds to Isolated Bacterial Codes 1304, 1305 and 1306; and also to Isolated Bacterial Code 1301
susceptible to Antimicrobial Code 1208 (Oxacillin) and 1606 (Cefoxitin).
Antibiogram is not created if the total number of isolates is less than 30.

11This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus aureus (MRSA)†
S

SorI

I

IorR

R

ND

GM (N=154,777)

GM(N=154,777)

103,115 0(66.6%) (0.0%)

3,534(2.3%)

68(0.0%)

46,750 1,310(30.2%) (0.8%)

EM (N=143,415)

EM(N=143,415)

20,151 0(14.1%) (0.0%)

12,995(9.1%)

117(0.1%)

110,152 0(76.8%) (0.0%)

CLDM (N=156,646)

CLDM(N=156,646)

107,002 0(68.3%) (0.0%)

2,259(1.4%)

61(0.0%)

47,288 36(30.2%) (0.0%)

LVFX (N=166,997)

LVFX(N=166,997)

17,191 0(10.3%) (0.0%)434(0.3%)

64(0.0%)

149,308 0(89.4%) (0.0%)

MINO (N=175,443)

MINO(N=175,443)

141,048 0(80.4%) (0.0%)

6,293(3.6%)

27(0.0%)

28,074 1(16.0%) (0.0%)

ST (N=130,882)

ST(N=130,882)

130,064 0(99.4%) (0.0%)0(0.0%)

0(0.0%)

723(0.6%)

95(0.1%)VCM (N=174,187)

VCM(N=174,187)

174,159 0(100%) (0.0%)26(0.0%)

0(0.0%)

0(0.0%)

2(0.0%)TEIC (N=153,290)

TEIC(N=153,290)

153,228 0(100%) (0.0%)14(0.0%)

0(0.0%)

7(0.0%)

41(0.0%)LZD (N=132,000)

LZD(N=132,000)

131,967 0(100%) (0.0%)0(0.0%)

0(0.0%)

31(0.0%)

2(0.0%)

0

10

20

30

40

50

60

70

80

90

100 (%)S

DAP(N=58,616)

DAP (N=58,616)

0

10

20

30

40

50

60

70

80

90

NS

58,334 282(99.5%) (0.5%)ND

0(0.0%)

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† S. aureus (MRSA) corresponds to Isolated Bacterial Codes 1303, and also to Isolated Bacterial Code 1301 Resistant to
Antimicrobial Code 1208 (Oxacillin) or 1606 (Cefoxitin).
Antibiogram is not created if the total number of isolates is less than 30.

12This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Staphylococcus epidermidis†
S

SorI

I

IorR

R

ND

PCG (N=72,953)

PCG(N=72,953)

10,118 0(13.9%) (0.0%)0(0.0%)

0(0.0%)

62,834 1(86.1%) (0.0%)

MPIPC (N=63,279)

MPIPC(N=63,279)

16,928 0(26.8%) (0.0%)0(0.0%)

0(0.0%)

46,351 0(73.2%) (0.0%)

VCM (N=86,473)

VCM(N=86,473)

86,460(100%)

1(0.0%)

8(0.0%)

0(0.0%)

3(0.0%)

1(0.0%)TEIC (N=78,332)

TEIC(N=78,332)

75,333 1(96.2%) (0.0%)

2,774(3.5%)

1(0.0%)

222(0.3%)

1(0.0%)

0

10

20

30

40

50

60

70

80

90

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† S. epidermidis corresponds to Isolated Bacterial Code 1312.
Antibiogram is not created if the total number of isolates is less than 30.

13This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Coagulase-negative staphylococci (CNS)†
S

SorI

I

IorR

R

ND

PCG (N=59,783)

PCG(N=59,783)

13,663 0(22.9%) (0.0%)0(0.0%)

0(0.0%)

46,119 1(77.1%) (0.0%)

MPIPC (N=55,633)

MPIPC(N=55,633)

19,162 0(34.4%) (0.0%)0(0.0%)

0(0.0%)

36,471 0(65.6%) (0.0%)

VCM (N=80,193)

VCM(N=80,193)

80,167(100%)

1(0.0%)

7(0.0%)

0(0.0%)

16(0.0%)

2(0.0%)TEIC (N=69,773)

TEIC(N=69,773)

68,772 0(98.6%) (0.0%)804(1.2%)

1(0.0%)

195(0.3%)

1(0.0%)

0

10

20

30

40

50

60

70

80

90

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† Coagulase-negative staphylococci (CNS) corresponds to Isolated Bacterial Codes 1311 and 1313-1325 (except Code 1312,
Staphylococcus epidermidis)
Antibiogram is not created if the total number of isolates is less than 30.

14This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*Enterococcus faecalis†
S

SorI

I

IorR

R

ND

PCG (N=117,159)

PCG(N=117,159)

115,345 0(98.5%) (0.0%)0(0.0%)

0(0.0%)

931(0.8%)

883(0.8%)ABPC (N=129,563)

ABPC(N=129,563)

129,337 0(99.8%) (0.0%)0(0.0%)

0(0.0%)

224(0.2%)

2(0.0%)EM (N=108,619)

EM(N=108,619)

23,473 0(21.6%) (0.0%)

34,946 137(32.2%) (0.1%)

50,063 0(46.1%) (0.0%)

LVFX (N=134,507)

LVFX(N=134,507)

122,131 0(90.8%) (0.0%)

1,146(0.9%)

11,204(8.3%)MINO (N=139,723)

MINO(N=139,723)

47,584 0(34.1%) (0.0%)

19,531 125(14.0%) (0.1%)

72,482 1(51.9%) (0.0%)

VCM (N=142,316)

VCM(N=142,316)

142,300 0(100%) (0.0%)7(0.0%)

0(0.0%)

9(0.0%)

0(0.0%)TEIC (N=124,347)

TEIC(N=124,347)

124,332 0(100%) (0.0%)

1(0.0%)

0(0.0%)

14(0.0%)

0(0.0%)

0

10

20

30

40

50

60

70

80

90

17
(0.0%)

9(0.0%)

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† E. faecalis corresponds to Isolated Bacterial Codes 1201 and 1202.
Antibiogram is not created if the total number of isolates is less than 30.

15This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*Enterococcus faecium†
S

SorI

I

IorR

R

ND

PCG (N=53,508)

PCG(N=53,508)

6,284
0(11.7%) (0.0%)0(0.0%)

0(0.0%)

46,621 603(87.1%) (1.1%)

ABPC (N=59,105)

ABPC(N=59,105)7,220
0(12.2%) (0.0%)0(0.0%)

0(0.0%)

51,840 45(87.7%) (0.1%)

EM(N=51,391)

4,313(8.4%)

6,154
71(12.0%) (0.1%)

40,853 0(79.5%) (0.0%)

LVFX (N=62,209)

LVFX(N=62,209)

6,320
0(10.2%) (0.0%)

1,765(2.8%)

63(0.1%)

54,058 3(86.9%) (0.0%)

MINO (N=64,243)

MINO(N=64,243)

28,473 0(44.3%) (0.0%)

15,510 52(24.1%) (0.1%)

20,208 0(31.5%) (0.0%)

VCM (N=65,363)

VCM(N=65,363)

63,594 0(97.3%) (0.0%)82(0.1%)

1(0.0%)

1,686(2.6%)

0(0.0%)TEIC (N=58,342)

TEIC(N=58,342)

57,344 0(98.3%) (0.0%)94(0.2%)

1(0.0%)

902(1.5%)

1(0.0%)LZD (N=49,958)

LZD(N=49,958)

49,619 0(99.3%) (0.0%)293(0.6%)

1(0.0%)

45(0.1%)

0(0.0%)EM (N=51,391)

0

10

20

30

40

50

60

70

80

90

0
(0.0%)

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† E. faecium corresponds to Isolated Bacterial Codes 1205 and 1206.
Antibiogram is not created if the total number of isolates is less than 30.

16This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pneumoniae(Cerebrospinal Fluid)†
S

SorI

I

IorR

R

0
(0.0%)ND

PCG (N=57)

PCG(N=57)

28
0(49.1%) (0.0%)0(0.0%)CTX (N=49)

CTX(N=49)

420(85.7%) (0.0%)

50(10.2%) (0.0%)2(4.1%)

0(0.0%)MEPM (N=56)

MEPM(N=56)

46
0(82.1%) (0.0%)5(8.9%)

0(0.0%)

5(8.9%)

0(0.0%)EM (N=45)

EM(N=45)

90(20.0%) (0.0%)

1(2.2%)

0(0.0%)

35
0(77.8%) (0.0%)

CLDM (N=45)

CLDM(N=45)

190(42.2%) (0.0%)0(0.0%)

0(0.0%)

26
0(57.8%) (0.0%)

LVFX (N=52)

LVFX(N=52)

50
0(96.2%) (0.0%)

1(1.9%)

0(0.0%)

1(1.9%)

0

10

20

30

40

50

60

70

80

90

VCM
(N=56)

10

20

30

40

50

60

70

80

90

0
(0.0%)

100 (%)VCM (N=56)0290(50.9%) (0.0%)

S

NS

ND

56
(100%)

0(0.0%)

0(0.0%)

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† S. pneumoniae corresponds to Isolated Bacterial Code 1131.
Antibiogram is not created if the total number of isolates is less than 30.

17This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pneumoniae(Other than Cerebrospinal Fluid)†
S

SorI

I

IorR

R

ND

PCG (N=14,510)

PCG(N=14,510)

13,960 0(96.2%) (0.0%)421(2.9%)

2(0.0%)

127(0.9%)

0(0.0%)CTX (N=12,372)

CTX(N=12,372)

11,806 0(95.4%) (0.0%)266(2.2%)

0(0.0%)

300(2.4%)

0(0.0%)MEPM (N=14,452)

MEPM(N=14,452)

10,785 1(74.6%) (0.0%)

2,385
0(16.5%) (0.0%)

1,277(8.8%)

4(0.0%)EM (N=12,750)

EM(N=12,750)

2,068
1(16.2%) (0.0%)

221(1.7%)

6(0.0%)

10,454 0(82.0%) (0.0%)

CLDM (N=12,386)

CLDM(N=12,386)

5,941
2(48.0%) (0.0%)

208(1.7%)

3(0.0%)

6,232
0(50.3%) (0.0%)

LVFX (N=14,805)

LVFX(N=14,805)

13,750 0(92.9%) (0.0%)108(0.7%)

0(0.0%)

944(6.4%)

0

10

20

30

40

50

60

70

80

90

100 (%)

VCM(N=14,140)

VCM (N=14,140)

0

10

20

30

40

50

60

70

80

90

3
(0.0%)S

NS

ND

14,140(100%)

0(0.0%)

0(0.0%)

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† S. pneumoniae corresponds to Isolated Bacterial Code 1131.
Antibiogram is not created if the total number of isolates is less than 30.

18This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Streptococcus pyogenes†
S

SorI

I

IorR

R

ND

EM (N=1,860)

EM(N=1,860)

1,303
1(70.1%) (0.1%)

16(0.9%)

1(0.1%)

539
0(29.0%) (0.0%)

CLDM (N=2,070)

CLDM(N=2,070)

1,689
1(81.6%) (0.0%)13(0.6%)

1(0.0%)

366
0(17.7%) (0.0%)

0

10

20

30

40

50

60

70

80

90

100 (%)SNSND

PCG (N=2,117)

PCG(N=2,117)2,117(100%)

0(0.0%)

0(0.0%)ABPC (N=2,130)

ABPC(N=2,130)2,121
0(99.6%) (0.0%)9(0.4%)CTX (N=1,801)

CTX(N=1,801)

1,800
0(99.9%) (0.0%)1(0.1%)

0

10

20

30

40

50

60

70

80

90

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† S. pyogenes corresponds to Isolated Bacterial Code 1111.
Antibiogram is not created if the total number of isolates is less than 30.

19This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Streptococcus agalactiae†
S

SorI

I

IorR

R

ND

EM (N=37,487)

EM(N=37,487)

23,519 394(62.7%) (1.1%)

479(1.3%)

5(0.0%)

13,090 0(34.9%) (0.0%)

CLDM (N=45,377)

CLDM(N=45,377)

34,685 565(76.4%) (1.2%)580(1.3%)

2(0.0%)

9,545
0(21.0%) (0.0%)

0

10

20

30

40

50

60

70

80

90

100 (%)SNSND

PCG (N=43,793)

PCG(N=43,793)

41,252 2,536(94.2%) (5.8%)

5(0.0%)ABPC (N=43,641)

ABPC(N=43,641)

42,729 507(97.9%) (1.2%)405(0.9%)CTX (N=31,718)

CTX(N=31,718)

31,348 368(98.8%) (1.2%)

2(0.0%)

0

10

20

30

40

50

60

70

80

90

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† S. agalactiae corresponds to Isolated Bacterial Code 1114.
Antibiogram is not created if the total number of isolates is less than 30.

20This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Escherichia coli†
S

SorI

I

IorR

R

ND

ABPC (N=358,902)

ABPC(N=358,902)

175,656 1(48.9%) (0.0%)

3,584(1.0%)

276(0.1%)

179,172 213(49.9%) (0.1%)

PIPC (N=352,001)

PIPC(N=352,001)

186,068 0(52.9%) (0.0%)

12,313
(3.5%)

325(0.1%)

153,191 104(43.5%) (0.0%)

TAZ/PIPC (N=326,287)

TAZ/PIPC(N=326,287)

312,854 207(95.9%) (0.1%)

4,845(1.5%)

22(0.0%)

8,343(2.6%)CEZ (N=379,774)

CEZ(N=379,774)

133,325 86,626 13,422(35.1%) (22.8%) (3.5%)0(0.0%)

141,184 5,217(37.2%) (1.4%)

CMZ (N=398,172)

CMZ(N=398,172)

391,996 2(98.4%) (0.0%)

3,278(0.8%)

6(0.0%)

2,884(0.7%)CTX (N=258,317)

CTX(N=258,317)

187,364 6(72.5%) (0.0%)

1,579(0.6%)

257(0.1%)

69,111 0(26.8%) (0.0%)

CAZ (N=390,324)

CAZ(N=390,324)

320,609 583(82.1%) (0.1%)

18,898(4.8%)

31(0.0%)

49,956 247(12.8%) (0.1%)

CFPM(N=362,758)

295,550 0(81.5%) (0.0%)

6,848(1.9%)

1,119(0.3%)

58,861 380(16.2%) (0.1%)

AZT (N=301,651)

AZT(N=301,651)

232,874 0(77.2%) (0.0%)

11,062(3.7%)

54(0.0%)

57,530 131(19.1%) (0.0%)

IPM (N=342,379)

IPM(N=342,379)

341,869 9(99.9%) (0.0%)354(0.1%)

1(0.0%)

146(0.0%)

0(0.0%)

MEPM(N=407,162)

406,705 8(99.9%) (0.0%)85(0.0%)

0(0.0%)

364(0.1%)

0(0.0%)AMK (N=400,312)

AMK(N=400,312)

399,229 0(99.7%) (0.0%)722(0.2%)

1(0.0%)

346(0.1%)

14(0.0%)

LVFX (N=398,196)

LVFX(N=398,196)

230,027 0(57.8%) (0.0%)

8,496(2.1%)

292(0.1%)

157,791 1,590(39.6%) (0.4%)

CFPM (N=362,758)

MEPM (N=407,162)

0

10

20

30

40

50

60

70

80

16
(0.0%)

6(0.0%)

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† E. coli corresponds to Isolated Bacterial Codes 2001-2007.
Antibiogram is not created if the total number of isolates is less than 30.

21This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Klebsiella pneumoniae†
S

SorI

I

IorR

R

ND

ABPC (N=174,552)

ABPC(N=174,552)

9,435(5.4%)

2(0.0%)

29,369 183(16.8%) (0.1%)

135,284 279(77.5%) (0.2%)

PIPC (N=169,964)

PIPC(N=169,964)

99,721 0(58.7%) (0.0%)

23,172 54(13.6%) (0.0%)

46,832 185(27.6%) (0.1%)

TAZ/PIPC (N=160,489)

TAZ/PIPC(N=160,489)

150,548 79(93.8%) (0.0%)

4,032(2.5%)

19(0.0%)

5,805(3.6%)CEZ (N=183,757)

CEZ(N=183,757)

87,678 54,074 4,242(47.7%) (29.4%) (2.3%)0(0.0%)

34,470 3,293(18.8%) (1.8%)

CMZ (N=193,632)

CMZ(N=193,632)

189,671 1(98.0%) (0.0%)

1,189(0.6%)

1(0.0%)

2,756(1.4%)CTX (N=124,914)

CTX(N=124,914)

108,617 4(87.0%) (0.0%)

480(0.4%)

53(0.0%)

15,760 0(12.6%) (0.0%)

CAZ (N=189,618)

CAZ(N=189,618)

166,726 319(87.9%) (0.2%)

2,944(1.6%)

0(0.0%)

19,489 140(10.3%) (0.1%)

CFPM(N=177,866)

159,284 0(89.6%) (0.0%)

1,863(1.0%)

251(0.1%)

16,263(9.1%)AZT (N=146,557)

AZT(N=146,557)

129,082 0(88.1%) (0.0%)

1,162(0.8%)

0(0.0%)

16,125 188(11.0%) (0.1%)

IPM (N=165,377)

IPM(N=165,377)

164,551 0(99.5%) (0.0%)618(0.4%)

0(0.0%)

208(0.1%)

0(0.0%)

MEPM(N=197,801)

196,935 0(99.6%) (0.0%)159(0.1%)

0(0.0%)

706(0.4%)

1(0.0%)AMK (N=194,640)

AMK(N=194,640)

194,411 0(99.9%) (0.0%)112(0.1%)

3(0.0%)

112(0.1%)

2(0.0%)

LVFX (N=192,244)

LVFX(N=192,244)

179,256 0(93.2%) (0.0%)

2,905(1.5%)

7(0.0%)

9,911(5.2%)

165(0.1%)

CFPM (N=177,866)

MEPM (N=197,801)

0

10

20

30

40

50

60

70

80

6
(0.0%)

14(0.0%)

205(0.1%)

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† K. pneumoniae corresponds to Isolated Bacterial Code 2351.
Antibiogram is not created if the total number of isolates is less than 30.

22This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*Enterobacter cloacae†
S

SorI

0
(0.0%)ABPC (N=66,059)

ABPC(N=66,059)

5,207(7.9%)PIPC (N=61,527)

PIPC(N=61,527)

TAZ/PIPC (N=59,998)

I

IorR

R

ND

6,621
36
(10.0%) (0.1%)

54,178 17(82.0%) (0.0%)

43,271 0(70.3%) (0.0%)

4,869(7.9%)

14(0.0%)

13,367 6(21.7%) (0.0%)

TAZ/PIPC(N=59,998)

47,468 26(79.1%) (0.0%)

6,111
28
(10.2%) (0.0%)

6,349
16
(10.6%) (0.0%)

CEZ (N=69,693)

CEZ(N=69,693)

511(0.7%)

411(0.6%)

255(0.4%)

0(0.0%)

68,484 32(98.3%) (0.0%)

CMZ (N=71,629)

CMZ(N=71,629)

4,092(5.7%)

0(0.0%)

4,391(6.1%)

36(0.1%)

63,098 12(88.1%) (0.0%)

CTX (N=48,848)

CTX(N=48,848)

30,347 5(62.1%) (0.0%)

1,419(2.9%)

42(0.1%)

17,035 0(34.9%) (0.0%)

CAZ (N=71,014)

CAZ(N=71,014)

48,612 115(68.5%) (0.2%)

2,003(2.8%)

1(0.0%)

20,269 14(28.5%) (0.0%)

CFPM(N=67,964)

64,286 0(94.6%) (0.0%)

1,136(1.7%)

75(0.1%)

2,464(3.6%)AZT (N=58,130)

AZT(N=58,130)40,025 0(68.9%) (0.0%)

2,137(3.7%)

1(0.0%)

15,937 30(27.4%) (0.1%)

IPM (N=62,027)

IPM(N=62,027)

58,960 7(95.1%) (0.0%)

2,508(4.0%)

0(0.0%)

550(0.9%)

2(0.0%)

MEPM(N=74,210)

73,519 6(99.1%) (0.0%)169(0.2%)

0(0.0%)

515(0.7%)

1(0.0%)AMK (N=73,178)

AMK(N=73,178)

73,055 0(99.8%) (0.0%)49(0.1%)

0(0.0%)

73(0.1%)

1(0.0%)

LVFX (N=71,907)

LVFX(N=71,907)

68,527 0(95.3%) (0.0%)

1,502(2.1%)

2(0.0%)

1,807(2.5%)

69(0.1%)

CFPM (N=67,964)

MEPM (N=74,210)

0

10

20

30

40

50

60

70

80

3
(0.0%)

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† E. cloacae corresponds to Isolated Bacterial Code 2151.
Antibiogram is not created if the total number of isolates is less than 30.

23This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*Enterobacter cloacae complex†
S

SorI

0
(0.0%)ABPC (N=67,434)

ABPC(N=67,434)

5,370(8.0%)PIPC (N=62,945)

PIPC(N=62,945)

TAZ/PIPC (N=61,177)

I

IorR

R

ND

6,821
37
(10.1%) (0.1%)

55,189 17(81.8%) (0.0%)

44,397 0(70.5%) (0.0%)

4,991(7.9%)

14(0.0%)

13,537 6(21.5%) (0.0%)

TAZ/PIPC(N=61,177)

48,483 26(79.3%) (0.0%)

6,186
28
(10.1%) (0.0%)

6,438
16
(10.5%) (0.0%)

CEZ (N=71,131)

CEZ(N=71,131)523(0.7%)

423(0.6%)

262(0.4%)

0(0.0%)

69,890 33(98.3%) (0.0%)

CMZ (N=73,108)

CMZ(N=73,108)

4,167(5.7%)

0(0.0%)

4,439(6.1%)

37(0.1%)

64,453 12(88.2%) (0.0%)

CTX (N=49,852)

CTX(N=49,852)

31,013 5(62.2%) (0.0%)

1,450(2.9%)

42(0.1%)

17,342 0(34.8%) (0.0%)

CAZ (N=72,503)

CAZ(N=72,503)

49,765 115(68.6%) (0.2%)

2,047(2.8%)

1(0.0%)

20,561 14(28.4%) (0.0%)

CFPM(N=69,416)

65,727 0(94.7%) (0.0%)

1,138(1.6%)

75(0.1%)

2,473(3.6%)AZT (N=59,255)

AZT(N=59,255)

40,916 0(69.1%) (0.0%)

2,174(3.7%)

1(0.0%)

16,134 30(27.2%) (0.1%)

IPM (N=63,391)

IPM(N=63,391)

60,232 7(95.0%) (0.0%)

2,584(4.1%)

0(0.0%)

566(0.9%)

2(0.0%)

MEPM(N=75,747)

75,047 6(99.1%) (0.0%)170(0.2%)

0(0.0%)

523(0.7%)

1(0.0%)AMK (N=74,663)

AMK(N=74,663)

74,537 0(99.8%) (0.0%)49(0.1%)

0(0.0%)

76(0.1%)

1(0.0%)

LVFX (N=73,409)

LVFX(N=73,409)

69,999 0(95.4%) (0.0%)

1,519(2.1%)

2(0.0%)

1,820(2.5%)

69(0.1%)

CFPM (N=69,416)

MEPM (N=75,747)

0

10

20

30

40

50

60

70

80

3
(0.0%)

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† E. cloacae complex correspond to Isolated Bacterial Codes 2151，2155，2157-2161.
Antibiogram is not created if the total number of isolates is less than 30.

24This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Klebsiella aerogenes†
S

SorI

I

IorR

R

ND

ABPC (N=38,564)

ABPC(N=38,564)

3,164(8.2%)

0(0.0%)

4,088
50(10.6%) (0.1%)

31,242 20(81.0%) (0.1%)

PIPC (N=35,871)

PIPC(N=35,871)

23,601 0(65.8%) (0.0%)

5,990
9(16.7%) (0.0%)

6,264
7(17.5%) (0.0%)

TAZ/PIPC (N=34,399)

TAZ/PIPC(N=34,399)

26,659 3(77.5%) (0.0%)5,1808(15.1%) (0.0%)

2,542(7.4%)CEZ (N=40,246)

CEZ(N=40,246)561(1.4%)

1,110(2.8%)

388(1.0%)

0(0.0%)

38,139 48(94.8%) (0.1%)

CMZ (N=41,502)

CMZ(N=41,502)

2,119(5.1%)

0(0.0%)

2,085(5.0%)

51(0.1%)

37,232 15(89.7%) (0.0%)

CTX (N=28,608)

CTX(N=28,608)

17,687 1(61.8%) (0.0%)625(2.2%)

34(0.1%)

10,261 0(35.9%) (0.0%)

CAZ (N=41,161)

CAZ(N=41,161)

27,205 101(66.1%) (0.2%)

1,467(3.6%)

8(0.0%)

12,371 9(30.1%) (0.0%)

CFPM(N=39,114)

38,279 0(97.9%) (0.0%)203(0.5%)

9(0.0%)

621(1.6%)AZT (N=34,014)

AZT(N=34,014)

24,281 0(71.4%) (0.0%)

2,628(7.7%)

6(0.0%)

7,077
22(20.8%) (0.1%)

IPM (N=35,870)

IPM(N=35,870)

31,188 3(86.9%) (0.0%)

4,199
1(11.7%) (0.0%)478(1.3%)

1(0.0%)

MEPM(N=42,475)

41,991 1(98.9%) (0.0%)116(0.3%)

1(0.0%)

366(0.9%)

0(0.0%)AMK (N=41,981)

AMK(N=41,981)

41,952 0(99.9%) (0.0%)14(0.0%)

0(0.0%)

15(0.0%)

0(0.0%)

LVFX (N=41,329)

LVFX(N=41,329)

40,662 0(98.4%) (0.0%)280(0.7%)

0(0.0%)

378(0.9%)

9(0.0%)

CFPM (N=39,114)

MEPM (N=42,475)

0

10

20

30

40

50

60

70

80

7
(0.0%)

2(0.0%)

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† K. aerogenes corresponds to Isolated Bacterial Code 2152.
Antibiogram is not created if the total number of isolates is less than 30.

25
This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Citrobacter freundii†
S

SorI

I

IorR

R

ND

ABPC (N=18,582)

ABPC(N=18,582)

5,046
0(27.2%) (0.0%)

2,423
48
(13.0%) (0.3%)

11,053 12(59.5%) (0.1%)

PIPC (N=17,482)

PIPC(N=17,482)

12,311 0(70.4%) (0.0%)

1,419(8.1%)

22(0.1%)

3,726
4(21.3%) (0.0%)

TAZ/PIPC (N=16,942)

TAZ/PIPC(N=16,942)

15,035 8(88.7%) (0.0%)

1,328(7.8%)

11(0.1%)

558(3.3%)CEZ (N=19,757)

CEZ(N=19,757)351(1.8%)

306(1.5%)

0(0.0%)

18,786 23(95.1%) (0.1%)

CMZ (N=20,067)

CMZ(N=20,067)

8,945
0(44.6%) (0.0%)

4,993
37
(24.9%) (0.2%)

6,090
2(30.3%) (0.0%)

CTX (N=13,710)

CTX(N=13,710)

9,590
3(69.9%) (0.0%)

218(1.6%)

22(0.2%)

3,877
0(28.3%) (0.0%)

CAZ (N=20,182)

CAZ(N=20,182)

14,565 40(72.2%) (0.2%)343(1.7%)

11(0.1%)

5,217
6(25.8%) (0.0%)

CFPM(N=19,174)

18,826 0(98.2%) (0.0%)97(0.5%)

10(0.1%)

241(1.3%)AZT (N=16,118)

AZT(N=16,118)

11,791 0(73.2%) (0.0%)577(3.6%)

12(0.1%)

3,731
7(23.1%) (0.0%)

IPM (N=17,558)

IPM(N=17,558)

17,034 0(97.0%) (0.0%)489(2.8%)

0(0.0%)

35(0.2%)

0(0.0%)

MEPM(N=21,141)

21,080 0(99.7%) (0.0%)13(0.1%)

0(0.0%)

48(0.2%)

0(0.0%)AMK (N=20,763)

AMK(N=20,763)

20,735 0(99.9%) (0.0%)13(0.1%)

0(0.0%)

15(0.1%)

0(0.0%)

LVFX (N=20,561)

LVFX(N=20,561)

19,527 0(95.0%) (0.0%)389(1.9%)

2(0.0%)

626(3.0%)

17(0.1%)

CFPM (N=19,174)

MEPM (N=21,141)

0

10

20

30

40

50

60

70

80

291
(1.5%)

2(0.0%)

0(0.0%)

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† C. freundii corresponds to Isolated Bacterial Code 2051.
Antibiogram is not created if the total number of isolates is less than 30.

26This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Citrobacter koseri†
S

SorI

I

IorR

R

ND

0
(0.0%)

1,044(6.1%)

26(0.2%)

15,979 3(92.8%) (0.0%)

ABPC (N=17,212)

ABPC(N=17,212)160(0.9%)PIPC (N=17,632)

PIPC(N=17,632)

7,535
0(42.7%) (0.0%)

5,381
5(30.5%) (0.0%)

4,711
0(26.7%) (0.0%)

TAZ/PIPC (N=16,193)

TAZ/PIPC(N=16,193)

15,363 4(94.9%) (0.0%)224(1.4%)

2(0.0%)

600(3.7%)CEZ (N=18,670)

CEZ(N=18,670)

10,052 5,713
422(53.8%) (30.6%) (2.3%)0(0.0%)

2,091
392(11.2%) (2.1%)

CMZ (N=19,649)

CMZ(N=19,649)

18,995 0(96.7%) (0.0%)304(1.5%)

0(0.0%)

350(1.8%)

0(0.0%)CTX (N=11,944)

CTX(N=11,944)

11,081 0(92.8%) (0.0%)69(0.6%)

1(0.0%)

793(6.6%)

0(0.0%)CAZ (N=19,105)

CAZ(N=19,105)

17,812 46(93.2%) (0.2%)

143(0.7%)

0(0.0%)

1,091(5.7%)

13(0.1%)

CFPM(N=17,808)

17,070 0(95.9%) (0.0%)103(0.6%)

5(0.0%)

630(3.5%)

0(0.0%)AZT (N=14,162)

AZT(N=14,162)

13,108 0(92.6%) (0.0%)85(0.6%)

0(0.0%)

969(6.8%)

0(0.0%)IPM (N=16,915)

IPM(N=16,915)

16,867 6(99.7%) (0.0%)27(0.2%)

0(0.0%)

15(0.1%)

0(0.0%)

MEPM(N=19,956)

19,929 6(99.9%) (0.0%)6(0.0%)

0(0.0%)

15(0.1%)

0(0.0%)AMK (N=19,738)

AMK(N=19,738)

19,706 0(99.8%) (0.0%)22(0.1%)

0(0.0%)

10(0.1%)

0(0.0%)

LVFX (N=19,429)

LVFX(N=19,429)

18,466 0(95.0%) (0.0%)

206(1.1%)

0(0.0%)

751(3.9%)

6(0.0%)

CFPM (N=17,808)

MEPM (N=19,956)

0

10

20

30

40

50

60

70

80

0
(0.0%)

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† C. koseri corresponds to Isolated Bacterial Code 2052.
Antibiogram is not created if the total number of isolates is less than 30.

27
This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Proteus mirabilis†
S

SorI

I

IorR

R

ND

ABPC (N=38,729)

ABPC(N=38,729)

25,535 0(65.9%) (0.0%)406(1.0%)

20(0.1%)

12,688 80(32.8%) (0.2%)

PIPC (N=42,239)

PIPC(N=42,239)

28,365 0(67.2%) (0.0%)

2,152(5.1%)

52(0.1%)

11,625 45(27.5%) (0.1%)

TAZ/PIPC (N=38,264)

TAZ/PIPC(N=38,264)

37,824 13(98.9%) (0.0%)130(0.3%)

5(0.0%)

292(0.8%)CEZ (N=44,464)

CEZ(N=44,464)

12,521 9,260
5,898
0(28.2%) (20.8%) (13.3%) (0.0%)

15,982 803(35.9%) (1.8%)

CMZ (N=45,761)

CMZ(N=45,761)

45,393 0(99.2%) (0.0%)

110(0.2%)

0(0.0%)

258(0.6%)CTX (N=26,061)

CTX(N=26,061)

21,161 0(81.2%) (0.0%)183(0.7%)

23(0.1%)

4,694
0(18.0%) (0.0%)

CAZ (N=44,222)

CAZ(N=44,222)

42,360 55(95.8%) (0.1%)

315(0.7%)

0(0.0%)

1,489(3.4%)

CFPM(N=40,520)

34,315 0(84.7%) (0.0%)590(1.5%)

68(0.2%)

5,378
169(13.3%) (0.4%)

AZT (N=31,902)

AZT(N=31,902)

28,966 0(90.8%) (0.0%)308(1.0%)

8(0.0%)

2,582(8.1%)IPM (N=22,089)

IPM(N=22,089)

11,519 1(52.1%) (0.0%)7,480
0(33.9%) (0.0%)

3,088
1(14.0%) (0.0%)

MEPM(N=46,732)

46,648 2(99.8%) (0.0%)36(0.1%)

0(0.0%)

46(0.1%)

0(0.0%)AMK (N=46,219)

AMK(N=46,219)

46,049 0(99.6%) (0.0%)81(0.2%)

0(0.0%)

89(0.2%)

0(0.0%)

LVFX (N=45,806)

LVFX(N=45,806)

35,412 0(77.3%) (0.0%)

3,646(8.0%)

14(0.0%)

6,657
77(14.5%) (0.2%)

CFPM (N=40,520)

MEPM (N=46,732)

0

10

20

30

40

50

60

70

80

0
(0.0%)

0(0.0%)

3(0.0%)

38(0.1%)

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† P. mirabilis corresponds to Isolated Bacterial Code 2201.
Antibiogram is not created if the total number of isolates is less than 30.

28This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Proteus vulgaris†
S

SorI

I

IorR

R

ND

0
(0.0%)

84(1.0%)

14(0.2%)

7,691
0(94.4%) (0.0%)

ABPC (N=8,149)

ABPC(N=8,149)360(4.4%)PIPC (N=7,717)

PIPC(N=7,717)

5,295
0(68.6%) (0.0%)

1,149
2(14.9%) (0.0%)

1,271
0(16.5%) (0.0%)

TAZ/PIPC (N=7,552)

TAZ/PIPC(N=7,552)

7,504
10(99.4%) (0.1%)

18(0.2%)

0(0.0%)

20(0.3%)CEZ (N=8,773)

CEZ(N=8,773)

65(0.7%)

77(0.9%)

53(0.6%)

0(0.0%)

8,566
12(97.6%) (0.1%)

CMZ (N=8,988)

CMZ(N=8,988)

8,916
0(99.2%) (0.0%)30(0.3%)

0(0.0%)

42(0.5%)CTX (N=6,089)

CTX(N=6,089)

4,483
0(73.6%) (0.0%)

238(3.9%)

3(0.0%)

1,365
0(22.4%) (0.0%)

CAZ (N=8,749)

CAZ(N=8,749)

8,572
32(98.0%) (0.4%)

83(0.9%)

0(0.0%)

62(0.7%)

0(0.0%)

CFPM(N=8,197)

8,060
0(98.3%) (0.0%)41(0.5%)

2(0.0%)

94(1.1%)

0(0.0%)AZT (N=7,049)

AZT(N=7,049)

6,017
0(85.4%) (0.0%)

139(2.0%)

0(0.0%)

893
0(12.7%) (0.0%)

IPM (N=6,588)

IPM(N=6,588)

2,849
0(43.2%) (0.0%)

2,240
0(34.0%) (0.0%)

1,499
0(22.8%) (0.0%)

MEPM(N=9,139)9,120
0(99.8%) (0.0%)9(0.1%)

0(0.0%)

10(0.1%)

0(0.0%)AMK (N=8,994)

AMK(N=8,994)

8,985
0(99.9%) (0.0%)

3(0.0%)

0(0.0%)

6(0.1%)

0(0.0%)

LVFX (N=8,981)

LVFX(N=8,981)

8,902
0(99.1%) (0.0%)30(0.3%)

1(0.0%)

47(0.5%)

1(0.0%)

CFPM (N=8,197)

MEPM (N=9,139)

0

10

20

30

40

50

60

70

80

90

0
(0.0%)

0(0.0%)

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† P. vulgaris corresponds to Isolated Bacterial Code 2202.
Antibiogram is not created if the total number of isolates is less than 30.

29This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Serratia marcescens†
S

SorI

I

IorR

R

ND

ABPC (N=35,559)

ABPC(N=35,559)

1,985(5.6%)

1(0.0%)

3,907
63(11.0%) (0.2%)

29,553 50(83.1%) (0.1%)

PIPC (N=35,602)

PIPC(N=35,602)

27,860 0(78.3%) (0.0%)

4,896
9(13.8%) (0.0%)

2,828(7.9%)

9(0.0%)

TAZ/PIPC (N=33,397)

TAZ/PIPC(N=33,397)

29,199 12(87.4%) (0.0%)

2,796(8.4%)

7(0.0%)

1,376(4.1%)

7(0.0%)CEZ (N=39,113)

CEZ(N=39,113)

25(0.1%)

11(0.0%)

15(0.0%)

0(0.0%)

39,032 30(99.8%) (0.1%)

CMZ (N=39,680)

CMZ(N=39,680)

31,509 1(79.4%) (0.0%)

3,344(8.4%)

10(0.0%)

4,814
2(12.1%) (0.0%)

CTX (N=11,514)

CTX(N=11,514)

8,657
1(75.2%) (0.0%)766(6.7%)

14(0.1%)

2,076
0(18.0%) (0.0%)

CAZ (N=39,507)

CAZ(N=39,507)

34,777 56(88.0%) (0.1%)

668(1.7%)

0(0.0%)

3,988
18(10.1%) (0.0%)

CFPM(N=36,857)

36,309 0(98.5%) (0.0%)168(0.5%)

12(0.0%)

365(1.0%)AZT (N=30,683)

AZT(N=30,683)

26,503 0(86.4%) (0.0%)942(3.1%)

1(0.0%)

3,228
9(10.5%) (0.0%)

IPM (N=20,322)

IPM(N=20,322)

18,754 0(92.3%) (0.0%)

1,115(5.5%)

0(0.0%)

453(2.2%)

0(0.0%)

MEPM(N=40,910)

40,816 6(99.8%) (0.0%)34(0.1%)

0(0.0%)

53(0.1%)

1(0.0%)AMK (N=40,620)

AMK(N=40,620)

40,282 0(99.2%) (0.0%)244(0.6%)

0(0.0%)

94(0.2%)

0(0.0%)

LVFX (N=39,970)

LVFX(N=39,970)

37,323 0(93.4%) (0.0%)

1,278(3.2%)

2(0.0%)

1,338(3.3%)

29(0.1%)

CFPM (N=36,857)

MEPM (N=40,910)

0

10

20

30

40

50

60

70

80

3
(0.0%)

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† S. marcescens corresponds to Isolated Bacterial Code 2101.
Antibiogram is not created if the total number of isolates is less than 30.

30This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Pseudomonas aeruginosa†
S

SorI

I

IorR

R

ND

PIPC (N=223,807)

PIPC(N=223,807)

180,994 0(80.9%) (0.0%)

21,078(9.4%)

49(0.0%)

21,624(9.7%)

62(0.0%)

TAZ/PIPC (N=201,973)

TAZ/PIPC(N=201,973)

169,687 46(84.0%) (0.0%)

16,311(8.1%)

69(0.0%)

15,814(7.8%)

46(0.0%)CAZ (N=221,033)

CAZ(N=221,033)

190,058 0(86.0%) (0.0%)

11,528(5.2%)

209(0.1%)

19,197(8.7%)

41(0.0%)

CFPM (N=212,498)

CFPM(N=212,498)

185,534 0(87.3%) (0.0%)

15,608(7.3%)

56(0.0%)

11,264(5.3%)

36(0.0%)AZT (N=176,832)

AZT(N=176,832)

130,263 0(73.7%) (0.0%)

23,115 267(13.1%) (0.2%)

22,904 283(13.0%) (0.2%)

IPM(N=202,639)

163,231 0(80.6%) (0.0%)

9,233(4.6%)

124(0.1%)

30,049 2(14.8%) (0.0%)

MEPM (N=228,253)

MEPM(N=228,253)

196,282 0(86.0%) (0.0%)

10,172(4.5%)

82(0.0%)

21,717(9.5%)

0(0.0%)

GM (N=193,104)

GM(N=193,104)

169,011 0(87.5%) (0.0%)

19,243 11(10.0%) (0.0%)

4,839(2.5%)

0(0.0%)

AMK(N=228,023)

223,520 0(98.0%) (0.0%)

3,020(1.3%)

2(0.0%)

1,479(0.6%)

2(0.0%)

LVFX(N=216,226)

186,694 0(86.3%) (0.0%)

11,908(5.5%)

36(0.0%)

17,552(8.1%)

36(0.0%)IPM (N=202,639)

AMK (N=228,023)

LVFX (N=216,226)

0

10

20

30

40

50

60

70

80

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† P. aeruginosa corresponds to Isolated Bacterial Code 4001.
Antibiogram is not created if the total number of isolates is less than 30.

31This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Acinetobacter spp.†
S

SorI

I

IorR

R

ND

PIPC (N=22,002)

PIPC(N=22,002)

17,046 0(77.5%) (0.0%)

2,556
13
(11.6%) (0.1%)

2,387
0(10.8%) (0.0%)

TAZ/PIPC (N=11,305)

TAZ/PIPC(N=11,305)

9,675
0(85.6%) (0.0%)528(4.7%)

88(0.8%)

1,014(9.0%)

0(0.0%)

SBT/ABPC (N=11,708)

SBT/ABPC(N=11,708)

11,000 0(94.0%) (0.0%)201(1.7%)

7(0.1%)

498(4.3%)

2(0.0%)CAZ (N=22,645)

CAZ(N=22,645)

19,203 0(84.8%) (0.0%)

1,102(4.9%)

218(1.0%)

2,121(9.4%)

1(0.0%)

CFPM (N=21,702)

CFPM(N=21,702)

19,047 0(87.8%) (0.0%)

1,133(5.2%)

16(0.1%)

1,504(6.9%)

2(0.0%)IPM (N=20,627)

IPM(N=20,627)

20,360 0(98.7%) (0.0%)33(0.2%)

2(0.0%)

207(1.0%)

25(0.1%)

MEPM(N=23,196)

22,765 0(98.1%) (0.0%)106(0.5%)

9(0.0%)

290(1.3%)

26(0.1%)

GM(N=19,819)

17,643 0(89.0%) (0.0%)576(2.9%)

0(0.0%)

1,599(8.1%)

1(0.0%)

AMK

22,174 0(97.1%) (0.0%)112(0.5%)

1(0.0%)

547(2.4%)

1(0.0%)(N=22,546)

19,510 0(86.5%) (0.0%)

1,094(4.9%)

0(0.0%)

1,940(8.6%)

2(0.0%)

ST(N=18,195)

16,443 0(90.4%) (0.0%)0(0.0%)

0(0.0%)

1,735(9.5%)

17(0.1%)MEPM (N=23,196)

GM (N=19,819)

AMK (N=22,835)(N=22,835)

LVFX

LVFX (N=22,546)

ST (N=18,195)
0

10

20

30

40

50

60

70

80

90 100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† Acinetobacter spp. correspond to Isolated Bacterial Codes 4400-4403.
Antibiogram is not created if the total number of isolates is less than 30.

32This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

Annual Open Report 2022 (All Facilities)
Japan Nosocomial Infections Surveillance (JANIS)【Inpatient】
Clinical Laboratory Division
7. Antimicrobial Susceptibility of Major Bacteria*
Haemophilus influenzae†
S

SorI

I

IorR

R

ND

ABPC (N=16,450)

ABPC(N=16,450)

7,417
3(45.1%) (0.0%)

2,910
0(17.7%) (0.0%)6,120
0(37.2%) (0.0%)

SBT/ABPC (N=16,352)

SBT/ABPC(N=16,352)

11,160 0(68.2%) (0.0%)0(0.0%)

0(0.0%)

5,190
2(31.7%) (0.0%)

CVA/AMPC (N=11,210)

CVA/AMPC(N=11,210)

9,310
0(83.1%) (0.0%)0(0.0%)

0(0.0%)

1,883
17(16.8%) (0.2%)

CAM (N=16,393)

CAM(N=16,393)

12,544 0(76.5%) (0.0%)

2,811
22
(17.1%) (0.1%)

959(5.9%)

57(0.3%)TC (N=1,088)

TC(N=1,088)

1,034
0(95.0%) (0.0%)5(0.5%)

49(4.5%)

0(0.0%)

0

10

20

30

40

50

60

70

80

90 100 (%)

S

CTX

NS

ND

(N=11,940)

11,757 183(98.5%) (1.5%)0(0.0%)MEPM (N=18,211)

MEPM(N=18,211)

17,650 551(96.9%) (3.0%)

10(0.1%)

LVFX (N=18,084)

LVFX(N=18,084)

16,357 1,717(90.5%) (9.5%)

10(0.1%)CTX (N=11,940)

0

10

20

30

40

50

60

70

80

0
(0.0%)

90

100 (%)

Inpatient specimens with MIC values reported by either the broth microdilution method or Etest are counted.
Duplicates based on the result of Antimicrobial Susceptibility Testing are not recounted within 30 days (See Appendix).
* Results are interpreted according to the CLSI2012 (M100-S22) criteria.
† H. influenzae corresponds to Isolated Bacterial Codes 3201, 3202, 3203, 3205, 3208, 3211, 3214, 3217, 3220 and 3223.
Antibiogram is not created if the total number of isolates is less than 30.

33This Open Report does not cover every data from facilities nationwide.
Date of Total Tabulation :April 24, 2023

Date of Publication (English Version) :July 28, 2023

【Appendix 1 Interpretive Criteria for Specific AMR Bacteria based on the Broth Microdilution Method】
Isolated
Bacterium
Methicillin-Resistant
Staphylococcus aureus(MRSA)
VancomycinResistant
Staphylococcus aureus(VRSA)
VancomycinResistant Enterococci(VRE)

Penicillin-Resistant
Streptococcus
pneumoniae(PRSP)
Multidrug-ResistantPseudomonas
aeruginosa(MDRP)

Multidrug-ResistantAcinetobacter spp.
(MDRA)

CarbapenemResistantEnterobacteriaceae(CRE)

Comments*

MIC Values by BrothMicrodilution Method

Isolated Bacterial
Code Ver.6.1

S. aureus resistant to oxacillin and/or
cefoxitin by the broth microdilution
method or methicillin-resistant S. aureus
detected on selective media
S. aureus resistant to vancomycin

oxacillin ≥ 4 μg/mL
cefoxitin ≥ 8 μg/mL

1301, 1303

vancomycin ≥ 16 μg/mL

1301,1303–1306

Enterococcus spp. resistant† tovancomycin by the broth microdilution
method or vancomycin-resistantenterococci detected on selective media

vancomycin ≥ 16 μg/mL†

1201,1202,1205,

Note: Excluding species that were not
identified within Enterococcus sp.
S. pneumoniae resistant† topenicillin G

P. aeruginosa satisfying all of thefollowing criteria:
1. Resistant† to carbapenems(imipenem and/or meropenem)
2. Resistant† to aminoglycosides(amikacin)
3. Resistant to fluoroquinolones (any ofnorfloxacin, ofloxacin, levofloxacin,
lomefloxacin, ciprofloxacin).
Acinetobacter spp. satisfying all of thefollowing criteria:
1. Resistant to carbapenems (imipenem
and/or meropenem)
2. Resistant† to aminoglycosides(amikacin)
3. Resistant to fluoroquinolones (any oflevofloxacin, ciprofloxacin)Enterobacteriaceae satisfying one of thefollowing criteria.
1. Resistant† to meropenem
2. Resistant† to imipenem and also
resistant to cefmetazole

1206,1209,1210,
1213–1217

penicillin G ≥ 0.125 μg/mL†

1131

1. imipenem ≥ 16 μg/mL†,
meropenem ≥ 16 μg/mL†
2. amikacin ≥ 32 μg/mL†
3. norfloxacin ≥ 16 μg/mL,
ofloxacin ≥ 8 μg/mL,
levofloxacin ≥ 8 μg/mL,
lomefloxacin≥ 8 μg/mL,
ciprofloxacin ≥ 4 μg/mL

4001

1. imipenem ≥ 16 μg/mL†,
meropenem ≥ 16 μg/mL†
2. amikacin ≥ 32 μg/mL†
3. levofloxacin ≥ 8 μg/mL,
ciprofloxacin ≥ 4 μg/mL

4400–4403

meropenem ≥ 2 μg/mL†,
imipenem ≥ 2 μg/mL†
and also
cefmetazole ≥ 64 μg/mL

2000-2691,
3150-3151

Isolated
Bacterium

Comments*

MIC Values by BrothMicrodilution Method

Isolated Bacterial
Code Ver.6.1

CarbapenemResistantPseudomonas
aeruginosa
3rd Generation
CephalosporinResistant Klebsiellapneumoniae

P. aeruginosa resistant to imipenem
and/or meropenem

imipenem ≥ 16 μg/mL†,
meropenem ≥ 16 μg/mL†

4001

K. pneumoniae resistant to cefotaxime
and/or ceftriaxone and/or ceftazidime

cefotaxime ≥ 4 μg/mL,
ceftriaxone ≥ 4 μg/mL,
ceftazidime ≥ 16 μg/mL2351

3rd Generation
CephalosporinResistantEscherichia coli
FluoroquinoloneResistantEscherichia coli

E. coli resistant to cefotaxime and/or
ceftriaxone and/or ceftazidime

cefotaxime ≥ 4 μg/mL,
ceftriaxone ≥ 4 μg/mL,
ceftazidime ≥ 16 μg/mL

2001–2007

E. coli resistant to fluoroquinolones (anyof norfloxacin, ofloxacin, levofloxacin,
lomefloxacin, and ciprofloxacin)

norfloxacin ≥ 16 μg/mL,
ofloxacin ≥ 8 μg/mL,
levofloxacin ≥ 8 μg/mL,
lomefloxacin ≥ 8 μg/mL,
ciprofloxacin ≥ 4 μg/mL

2001–2007* In principle, RIS interpretation is based on the CLSI2012 (M100-S22) guidelines† Criteria are based on the Infectious Diseases Control Law

【Appendix 2 Method to Eliminate Duplicates of Annual Report】
1. Rule of Counting Days
“Day 1” is defined as the day after the "Specimen Reception Date". For example, if
a specimen is received on March 1, “Day 1” will be March 2 and “Day 30” will be
March 31.
wi thin 30 days
Example)Ma rchApri lMar 31"Da y 30"

Mar 2
"Da y 1"
Mar 1
"Specimen
Reception Date"

Example28 daysSpecimen
Reception Date

2. Number of "Specimen-submitting Patients"
The number of “Specimen-submitting Patients” is equal to the number of
inpatients whose specimens were submitted, regardless of the specimen sources.
If more than one specimen is submitted by one patient within 30 days, thenumber of “Specimen-submitting Patients” is defined as one. This is how weeliminate duplicates.
Example)Speci men
Receiption Date

3. Number of Patients with Major/Specific AMR Bacteria
The same method used to eliminate duplicate “Specimen-submitting Patients”
records is applied to “Patients with Major/Specific AMR Bacteria”. If more than one
identical bacterium is isolated from the same patient within 30 days, the numberof “Patients with Major/Specific AMR Bacteria” is not recounted.
To obtain the number of “Patients with Specific AMR Bacteria”, first the data
regarding pathogens which meet “Specific AMR Bacteria” criteria are extracted.
Then the method mentioned above is applied to eliminate duplicates.

Ma rchMar 2Apri lMar 30

Apr 10

Ma y
May 15Speci men
Speci mens ubmitting
Pa ti ents

The number of "Specimen-submitting
Pa ti ents" is not recounted i f thes econd specimen is s ubmitted within
30 da ys

The number of "Specimen-submitting
Pa ti ents" is recounted if the second
s pecimen is submitted on after 31
da ys

Ma rchMar 2

35 days

39 days

Apri lMar 30

Apr 10

Ma y
May 15Specimen
Pts with Major/
Specific AMR
bacteria

The number of "Pa tients with
Ma jor/Specific AMR Ba cteria" is notrecounted i f an i solated pathogen is
the s ame species as one identified
wi thin the past 30 da ys

The number of "Pa tiens with
Ma jor/Specific AMR Ba cteria" isrecounted i f the same pathogen i s
i s olated again on or a fter 31 da ys

4. Definition of Isolates Based on the Results of Antimicrobial Susceptibility Testing(AST)
If the AST results differ* between the same bacteria isolated within 30 days, eachof them is counted separately.
*Difference of AST is determined by satisfying any of the following four criteria:① More than four-fold difference in the MIC value; however,
MIC > 2 is equivalent to MIC ≥ 4 and is interpreted as MIC = 4, and
MIC < 16 is equivalent to MIC ≦ 16 and is interpreted as MIC = 16
② Findings of “R and S” on RIS interpretation③ Findings of “- and ++”, “+ and +++”, or “- and +++” on +/- interpretation④ Fewer than five duplicate antimicrobial agents among testings

【Appendix 2 Method to Eliminate Duplicates of Annual Report】
5. Method for Eliminating Duplicates Based on the Results of AST-

The following method will be applied to eliminate duplicates if “Identical Bacteria”
are detected more than once from the same patient within 30 days, according to
the criteria in Section 4.
With regard to the “Specimen Reception Date”, whichever is the earliest will be
adoptedData in which the greatest number of antimicrobial agents tested will be adopted
as the “Results of AST”
Adopted Specimen
Reception Date

Adopted Resultof AST

Example 1

Number of Antimicrobial Agents Tested: SEVEN on March 1 and ONE on March 31

Mar 1Within 30 days

Mar 31

SEVEN

March 1

SEVEN

ONE

Example 2

Number of Antimicrobial Agents Tested: TWO on March 1 and FIVE on March 31

Mar 1


TWO

Within 30 days

Mar 31March 1FIVE
FIVE

【Appendix 3 Box Plot Chart】
1. Box Plot Chart
The chart represents the data distribution of the facilities.

Example※Percentile represents the position of a single data value within a group of
samples in ascending order. For example, if a group contains 100 samples,
then the 10th percentile refers to the position of the 10th smallest value inthe group.
ｎn

2.

Box Plot Chart of Feedback Reports

Example